18 0 2 0 2 B-lower_bound
years 3 8 3 8 I-lower_bound
or 9 11 9 11 O
older 12 17 12 17 O
at 18 20 18 20 O
the 21 24 21 24 O
time 25 29 25 29 O
of 30 32 30 32 O
dose 33 37 33 37 O
initiation 38 48 38 48 O

A 0 1 49 50 O
history 2 9 51 58 O
of 10 12 59 61 O
any 13 16 62 65 O
major 17 22 66 71 O
surgery 23 30 72 79 B-treatment
within 31 37 80 86 O
6 38 39 87 88 B-upper_bound
weeks 40 45 89 94 I-upper_bound
prior 46 51 95 100 I-upper_bound
to 52 54 101 103 O
dosing 55 61 104 110 O

Absolute 0 8 111 119 B-clinical_variable
neutrophil 9 19 120 130 I-clinical_variable
count 20 25 131 136 I-clinical_variable
( 26 27 137 138 I-clinical_variable
ANC 27 30 138 141 I-clinical_variable
) 30 31 141 142 I-clinical_variable
≥1000 32 37 143 148 O
/ 37 38 148 149 I-lower_bound
mm3 38 41 149 152 I-lower_bound

An 0 2 153 155 O
existing 3 11 156 164 O
diagnosis 12 21 165 174 O
of 22 24 175 177 O
HIV 25 28 178 181 B-chronic_disease
, 28 29 181 182 O
hepatitis 30 39 183 192 B-chronic_disease
B 40 41 193 194 I-chronic_disease
, 41 42 194 195 O
hepatitis 43 52 196 205 B-chronic_disease
C 53 54 206 207 I-chronic_disease
, 54 55 207 208 O
or 56 58 209 211 O
any 59 62 212 215 O
current 63 70 216 223 O
laboratory 71 81 224 234 O
findings 82 90 235 243 O
or 91 93 244 246 O
clinical 94 102 247 255 O
signs 103 108 256 261 O
and 109 112 262 265 O
symptoms 113 121 266 274 O
that 122 126 275 279 O
suggest 127 134 280 287 O
these 135 140 288 293 O
conditions 141 151 294 304 O

Any 0 3 305 308 O
allergic 4 12 309 317 O
reaction 13 21 318 326 O
to 22 24 327 329 O
a 25 26 330 331 O
previously 27 37 332 342 O
administered 38 50 343 355 O
monoclonal 51 61 356 366 B-allergy_name
antibody 62 70 367 375 I-allergy_name
or 71 73 376 378 O
other 74 79 379 384 O
therapeutic 80 91 385 396 B-allergy_name
protein 92 99 397 404 I-allergy_name

Any 0 3 405 408 O
concomitant 4 15 409 420 O
serious 16 23 421 428 O
physical 24 32 429 437 O
illness 33 40 438 445 O
other 41 46 446 451 O
than 47 51 452 456 O
cancer 52 58 457 463 B-cancer
( 59 60 464 465 O
i.e. 60 64 465 469 O
, 64 65 469 470 O
immune 66 72 471 477 B-chronic_disease
deficiency 73 83 478 488 I-chronic_disease
disease 84 91 489 496 I-chronic_disease
, 91 92 496 497 O
bleeding 93 101 498 506 B-chronic_disease
disorder 102 110 507 515 I-chronic_disease
, 110 111 515 516 O
etc 112 115 517 520 O
. 115 116 520 521 O
) 116 117 521 522 O
within 118 124 523 529 O
1 125 126 530 531 B-upper_bound
year 127 131 532 536 I-upper_bound
prior 132 137 537 542 I-upper_bound
to 138 140 543 545 O
dosing 141 147 546 552 O

Any 0 3 553 556 O
condition 4 13 557 566 O
that 14 18 567 571 O
requires 19 27 572 580 O
or 28 30 581 583 O
is 31 33 584 586 O
likely 34 40 587 593 O
to 41 43 594 596 O
require 44 51 597 604 O
treatment 52 61 605 614 B-treatment
with 62 66 615 619 I-treatment
systemic 67 75 620 628 I-treatment
corticosteroids 76 91 629 644 I-treatment
within 92 98 645 651 O
the 99 102 652 655 O
Core 103 107 656 660 O
Study 108 113 661 666 O
Period 114 120 667 673 O
and 121 124 674 677 O
short 125 130 678 683 O
term 131 135 684 688 O
follow 136 142 689 695 O
- 142 143 695 696 O
up 143 145 696 698 O

Any 0 3 699 702 O
history 4 11 703 710 O
of 12 14 711 713 O
Stevens 15 22 714 721 B-chronic_disease
- 22 23 721 722 I-chronic_disease
Johnson 23 30 722 729 I-chronic_disease
syndrome 31 39 730 738 I-chronic_disease

Any 0 3 739 742 O
history 4 11 743 750 O
of 12 14 751 753 O
systemic 15 23 754 762 B-treatment
anticancer 24 34 763 773 I-treatment
therapy 35 42 774 781 I-treatment
( 43 44 782 783 O
standard 44 52 783 791 O
or 53 55 792 794 O
experimental 56 68 795 807 O
) 68 69 807 808 O
completed 70 79 809 818 O
within 80 86 819 825 O
30 87 89 826 828 B-upper_bound
days 90 94 829 833 I-upper_bound
prior 95 100 834 839 I-upper_bound
to 101 103 840 842 O
dosing 104 110 843 849 O

Any 0 3 850 853 O
significant 4 15 854 865 O
systemic 16 24 866 874 B-chronic_disease
infection 25 34 875 884 I-chronic_disease
within 35 41 885 891 O
4 42 43 892 893 B-upper_bound
weeks 44 49 894 899 I-upper_bound
prior 50 55 900 905 I-upper_bound
to 56 58 906 908 O
dosing 59 65 909 915 O

Clinically 0 10 916 926 O
significant 11 22 927 938 O
heart 23 28 939 944 B-chronic_disease
disease 29 36 945 952 I-chronic_disease
, 36 37 952 953 O
defined 38 45 954 961 O
as 46 48 962 964 O
NYHA 49 53 965 969 B-clinical_variable
Class 54 59 970 975 I-clinical_variable
III 60 63 976 979 B-lower_bound
or 64 66 980 982 O
IV 67 69 983 985 B-upper_bound

Evidence 0 8 986 994 O
of 9 11 995 997 O
clinically 12 22 998 1008 O
significant 23 34 1009 1020 O
of 35 37 1021 1023 O
central 38 45 1024 1031 B-cancer
nervous 46 53 1032 1039 I-cancer
system 54 60 1040 1046 I-cancer
( 61 62 1047 1048 I-cancer
CNS 62 65 1048 1051 I-cancer
) 65 66 1051 1052 I-cancer
metastases 67 77 1053 1063 I-cancer
or 78 80 1064 1066 O
symptomatic 81 92 1067 1078 O
CNS 93 96 1079 1082 B-cancer
metastases 97 107 1083 1093 I-cancer
within 108 114 1094 1100 O
30 115 117 1101 1103 B-upper_bound
days 118 122 1104 1108 I-upper_bound
prior 123 128 1109 1114 I-upper_bound
to 129 131 1115 1117 O
dosing 132 138 1118 1124 O

Hemoglobin 0 10 1125 1135 B-clinical_variable
( 11 12 1136 1137 I-clinical_variable
Hgb 12 15 1137 1140 I-clinical_variable
) 15 16 1140 1141 I-clinical_variable
≥ 17 18 1142 1143 O
9.0 19 22 1144 1147 B-lower_bound
g 23 24 1148 1149 I-lower_bound
/ 24 25 1149 1150 I-lower_bound
dL 25 27 1150 1152 I-lower_bound

Histologically 0 14 1153 1167 O
confirmed 15 24 1168 1177 O
unresectable 25 37 1178 1190 O
solid 38 43 1191 1196 B-cancer
tumor 44 49 1197 1202 I-cancer
malignancy 50 60 1203 1213 B-cancer
with 61 65 1214 1218 O
at 66 68 1219 1221 O
least 69 74 1222 1227 O
1 75 76 1228 1229 B-lower_bound
measurable 77 87 1230 1240 O
lesion 88 94 1241 1247 O

Karnofsky 0 9 1248 1257 B-clinical_variable
Performance 10 21 1258 1269 I-clinical_variable
Status 22 28 1270 1276 I-clinical_variable
≥70 29 32 1277 1280 O
in 33 35 1281 1283 O
the 36 39 1284 1287 O
30 40 42 1288 1290 B-upper_bound
day 43 46 1291 1294 I-upper_bound
baseline 47 55 1295 1303 O
period 56 62 1304 1310 O
immediately 63 74 1311 1322 O
prior 75 80 1323 1328 O
to 81 83 1329 1331 O
dosing 84 90 1332 1338 O

Life 0 4 1339 1343 B-clinical_variable
expectancy 5 15 1344 1354 I-clinical_variable
> 16 17 1355 1356 O
12 18 20 1357 1359 B-lower_bound
weeks 21 26 1360 1365 I-lower_bound

Males 0 5 1366 1371 B-gender

Metastatic 0 10 1372 1382 O
NSCLC 11 16 1383 1388 B-cancer
that 17 21 1389 1393 O
is 22 24 1394 1396 O
not 25 28 1397 1400 O
ALK+ 29 33 1401 1405 B-cancer
and 34 37 1406 1409 O
does 38 42 1410 1414 O
not 43 46 1415 1418 O
have 47 51 1419 1423 O
a 52 53 1424 1425 O
EGFR 54 58 1426 1430 O
sensitizing 59 70 1431 1442 O
mutation 71 79 1443 1451 O

Platelets 0 9 1452 1461 B-clinical_variable
( 10 11 1462 1463 I-clinical_variable
Plts 11 15 1463 1467 I-clinical_variable
) 15 16 1467 1468 I-clinical_variable
≥ 17 18 1469 1470 O
100,000 19 26 1471 1478 B-lower_bound
/ 26 27 1478 1479 I-lower_bound
μl 27 29 1479 1481 I-lower_bound

Previously 0 10 1482 1492 O
treated 11 18 1493 1500 O
for 19 22 1501 1504 O
advanced 23 31 1505 1513 O
cancer 32 38 1514 1520 B-cancer
with 39 43 1521 1525 O
no 44 46 1526 1528 O
additional 47 57 1529 1539 O
therapy 58 65 1540 1547 B-treatment
options 66 73 1548 1555 O
available 74 83 1556 1565 O
known 84 89 1566 1571 O
to 90 92 1572 1574 O
prolong 93 100 1575 1582 O
survival 101 109 1583 1591 O

Previously 0 10 1592 1602 O
treated 11 18 1603 1610 O
for 19 22 1611 1614 O
an 23 25 1615 1617 O
advanced 26 34 1618 1626 O
cancer 35 41 1627 1633 B-cancer
and 42 45 1634 1637 O
there 46 51 1638 1643 O
are 52 55 1644 1647 O
no 56 58 1648 1650 O
curative 59 67 1651 1659 B-treatment
therapy 68 75 1660 1667 I-treatment
options 76 83 1668 1675 O
available 84 93 1676 1685 O

Serum 0 5 1686 1691 B-clinical_variable
aspartate 6 15 1692 1701 I-clinical_variable
aminotransferase 16 32 1702 1718 I-clinical_variable
( 33 34 1719 1720 I-clinical_variable
AST 34 37 1720 1723 I-clinical_variable
) 37 38 1723 1724 I-clinical_variable
and 39 42 1725 1728 I-clinical_variable
alanine 43 50 1729 1736 I-clinical_variable
aminotransferase 51 67 1737 1753 I-clinical_variable
( 68 69 1754 1755 I-clinical_variable
ALT 69 72 1755 1758 I-clinical_variable
) 72 73 1758 1759 I-clinical_variable
≤2.5 74 78 1760 1764 O
X 79 80 1765 1766 I-upper_bound
ULN 81 84 1767 1770 I-upper_bound

Serum 0 5 1771 1776 B-clinical_variable
creatinine 6 16 1777 1787 I-clinical_variable
( 17 18 1788 1789 I-clinical_variable
Cr 18 20 1789 1791 I-clinical_variable
) 20 21 1791 1792 I-clinical_variable
≤1.5 22 26 1793 1797 O
X 27 28 1798 1799 I-upper_bound
upper 29 34 1800 1805 I-upper_bound
limit 35 40 1806 1811 I-upper_bound
of 41 43 1812 1814 I-upper_bound
normal 44 50 1815 1821 I-upper_bound
( 51 52 1822 1823 I-upper_bound
ULN 52 55 1823 1826 I-upper_bound
) 55 56 1826 1827 I-upper_bound

Serum 0 5 1828 1833 B-clinical_variable
total 6 11 1834 1839 I-clinical_variable
and 12 15 1840 1843 I-clinical_variable
( 16 17 1844 1845 I-clinical_variable
T 17 18 1845 1846 I-clinical_variable
-Bil 19 23 1847 1851 I-clinical_variable
) 24 25 1852 1853 I-clinical_variable
≤1.5 26 30 1854 1858 O
X 31 32 1859 1860 I-upper_bound
ULN 33 36 1861 1864 I-upper_bound

Subjects 0 8 1865 1873 O
on 9 11 1874 1876 O
any 12 15 1877 1880 O
immunomodulatory 16 32 1881 1897 B-treatment
drug 33 37 1898 1902 I-treatment

Subjects 0 8 1903 1911 O
on 9 11 1912 1914 O
prophylaxis 12 23 1915 1926 B-treatment
for 24 27 1927 1930 O
herpes 28 34 1931 1937 B-chronic_disease
who 35 38 1938 1941 O
started 39 46 1942 1949 O
taking 47 53 1950 1956 O
medication 54 64 1957 1967 B-treatment
at 65 67 1968 1970 O
least 68 73 1971 1976 O
30 74 76 1977 1979 B-lower_bound
days 77 81 1980 1984 I-lower_bound
prior 82 87 1985 1990 I-lower_bound
to 88 90 1991 1993 O
study 91 96 1994 1999 O
entry 97 102 2000 2005 O
, 102 103 2005 2006 O
should 104 110 2007 2013 O
continue 111 119 2014 2022 O
to 120 122 2023 2025 O
take 123 127 2026 2030 O
the 128 131 2031 2034 O
prescribed 132 142 2035 2045 O
medication 143 153 2046 2056 O
for 154 157 2057 2060 O
the 158 161 2061 2064 O
duration 162 170 2065 2073 O
of 171 173 2074 2076 O
the 174 177 2077 2080 O
study 178 183 2081 2086 O

Subjects 0 8 2087 2095 O
that 9 13 2096 2100 O
have 14 18 2101 2105 O
had 19 22 2106 2109 O
a 23 24 2110 2111 O
myocardial 25 35 2112 2122 B-chronic_disease
infarction 36 46 2123 2133 I-chronic_disease
within 47 53 2134 2140 O
the 54 57 2141 2144 O
last 58 62 2145 2149 B-upper_bound
6 63 64 2150 2151 I-upper_bound
months 65 71 2152 2158 I-upper_bound

Subjects 0 8 2159 2167 O
with 9 13 2168 2172 O
a 14 15 2173 2174 O
history 16 23 2175 2182 O
of 24 26 2183 2185 O
herpes 27 33 2186 2192 B-chronic_disease
zoster 34 40 2193 2199 I-chronic_disease
who 41 44 2200 2203 O
have 45 49 2204 2208 O
had 50 53 2209 2212 O
an 54 56 2213 2215 O
outbreak 57 65 2216 2224 O
within 66 72 2225 2231 O
the 73 76 2232 2235 O
last 77 81 2236 2240 O
year 82 86 2241 2245 O

Subjects 0 8 2246 2254 O
with 9 13 2255 2259 O
active 14 20 2260 2266 O
herpes 21 27 2267 2273 B-chronic_disease
simplex 28 35 2274 2281 I-chronic_disease
or 36 38 2282 2284 O
herpes 39 45 2285 2291 B-chronic_disease
zoster 46 52 2292 2298 I-chronic_disease

Unresolved 0 10 2299 2309 O
immune- 11 18 2310 2317 B-chronic_disease
related 19 26 2318 2325 I-chronic_disease
adverse 27 34 2326 2333 I-chronic_disease
events 35 41 2334 2340 I-chronic_disease
following 42 51 2341 2350 O
prior 52 57 2351 2356 B-treatment
biological 58 68 2357 2367 I-treatment
therapy 69 76 2368 2375 I-treatment

Use 0 3 2376 2379 O
of 4 6 2380 2382 O
any 7 10 2383 2386 O
investigational 11 26 2387 2402 B-treatment
drugs 27 32 2403 2408 I-treatment
within 33 39 2409 2415 O
30 40 42 2416 2418 B-upper_bound
days 43 47 2419 2423 I-upper_bound
prior 48 53 2424 2429 I-upper_bound
to 54 56 2430 2432 O
dosing 57 63 2433 2439 O

female 0 6 2440 2446 B-gender
subjects 7 15 2447 2455 I-gender
of 16 18 2456 2458 O
childbearing 19 31 2459 2471 O
age 32 35 2472 2475 B-age
must 36 40 2476 2480 O
be 41 43 2481 2483 O
either 44 50 2484 2490 O
surgically 51 61 2491 2501 O
sterile 62 69 2502 2509 O
, 69 70 2509 2510 O
postmenopausal 71 85 2511 2525 O
for 86 89 2526 2529 O
at 90 92 2530 2532 O
least 93 98 2533 2538 O
1 99 100 2539 2540 B-lower_bound
year 101 105 2541 2545 I-lower_bound
, 105 106 2545 2546 O
or 107 109 2547 2549 O
using 110 115 2550 2555 B-contraception_consent
an 116 118 2556 2558 I-contraception_consent
acceptable 119 129 2559 2569 I-contraception_consent
method 130 136 2570 2576 I-contraception_consent
of 137 139 2577 2579 I-contraception_consent
contraception 140 153 2580 2593 I-contraception_consent

females 0 7 2594 2601 B-gender

metastatic 0 10 2602 2612 O
gastric 11 18 2613 2620 B-cancer
cancer 19 25 2621 2627 I-cancer

metastatic 0 10 2628 2638 B-cancer
triple 11 17 2639 2645 I-cancer
negative 18 26 2646 2654 I-cancer
breast 27 33 2655 2661 I-cancer
cancer 34 40 2662 2668 I-cancer
that 41 45 2669 2673 O
has 46 49 2674 2677 O
received 50 58 2678 2686 O
prior 59 64 2687 2692 B-treatment
taxane 65 71 2693 2699 I-treatment
and 72 75 2700 2703 O
anthracycline 76 89 2704 2717 B-treatment
therapy 90 97 2718 2725 I-treatment

